可切除胰腺癌的新辅助治疗：永存时间偏倚及其校正 - Suppr

Neoadjuvant Therapy in Resectable Pancreatic Cancer: Immortal Time Bias and Its Correction.

作者信息

Lai Tzu-Yu, Hu Yu-Wen

机构信息

Tzu-Yu Lai, Taipei Veterans General Hospital, Taipei, Taiwan; and Yu-Wen Hu, Taipei Veterans General Hospital and Institute of Public Health, National Yang-Ming University, Taipei, Taiwan.

出版信息

J Clin Oncol. 2017 May 10;35(14):1623. doi: 10.1200/JCO.2016.71.2273. Epub 2017 Jan 30.

DOI:10.1200/JCO.2016.71.2273

PMID:28135147

Abstract

摘要

相似文献

Neoadjuvant Therapy in Resectable Pancreatic Cancer: Immortal Time Bias and Its Correction.可切除胰腺癌的新辅助治疗：永存时间偏倚及其校正

J Clin Oncol. 2017 May 10;35(14):1623. doi: 10.1200/JCO.2016.71.2273. Epub 2017 Jan 30.

Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.新辅助治疗与直接手术治疗可切除胰腺腺癌的对比：一项全国性倾向评分匹配分析。

Surgery. 2017 Mar;161(3):592-601. doi: 10.1016/j.surg.2016.08.040. Epub 2016 Oct 27.

Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.可切除胰腺癌的辅助和新辅助治疗：随机对照试验的系统评价

Med Oncol. 2016 Mar;33(3):28. doi: 10.1007/s12032-016-0742-z. Epub 2016 Feb 17.

Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.新辅助治疗后切除与直接切除可切除胰腺癌：倾向评分匹配分析。

J Clin Oncol. 2017 Feb 10;35(5):515-522. doi: 10.1200/JCO.2016.68.5081. Epub 2016 Sep 30.

Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.可切除边缘性胰腺癌及新辅助放化疗的作用

Updates Surg. 2016 Sep;68(3):235-239. doi: 10.1007/s13304-016-0392-x. Epub 2016 Sep 15.

Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.与直接手术相比，新辅助治疗可切除和边界可切除胰腺癌后的长期结局：一项意向性分析比较研究的荟萃分析。

Surg Today. 2019 Apr;49(4):295-299. doi: 10.1007/s00595-019-01786-w. Epub 2019 Mar 15.

Patient Selection for Neoadjuvant Therapy in Early-Stage Pancreatic Cancer.早期胰腺癌新辅助治疗的患者选择

J Clin Oncol. 2017 May 10;35(14):1622-1623. doi: 10.1200/JCO.2016.71.2315. Epub 2017 Jan 30.

Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.比较可切除或交界可切除胰腺癌患者术前手术与新辅助治疗的荟萃分析。

Br J Surg. 2018 Jul;105(8):946-958. doi: 10.1002/bjs.10870. Epub 2018 Apr 30.

Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.肽受体放射性核素治疗作为可切除或潜在可切除胰腺神经内分泌肿瘤的新辅助治疗。

Surgery. 2018 Apr;163(4):761-767. doi: 10.1016/j.surg.2017.11.007. Epub 2017 Dec 25.

Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.可切除胰腺癌的新辅助治疗与辅助治疗：放疗的作用演变

Semin Radiat Oncol. 2014 Apr;24(2):113-25. doi: 10.1016/j.semradonc.2013.11.002.

引用本文的文献

Survival Analysis of Conversion Surgery in Borderline Resectable and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma Addressing Selection and Immortal Time Bias: A Retrospective Single-Center Study.边界可切除和局部进展不可切除胰腺导管腺癌中转化手术的生存分析：解决选择和不朽时间偏倚的回顾性单中心研究。

Ann Surg Oncol. 2024 Dec;31(13):8744-8755. doi: 10.1245/s10434-024-16203-x. Epub 2024 Oct 3.

Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience.局部晚期不可切除胰腺癌患者通过诱导化疗和转化手术提高生存率：单机构经验

Am J Cancer Res. 2022 May 15;12(5):2189-2202. eCollection 2022.

Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma.2018/2019年重要更新：胰腺导管腺癌外科治疗的当前热点

Ann Gastroenterol Surg. 2020 Aug 9;5(1):7-23. doi: 10.1002/ags3.12379. eCollection 2021 Jan.

Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer-Where Is the Least Harm and Most Benefit?确定可切除边缘性静脉侵犯胰腺癌的最佳手术路径——何处危害最小且获益最大？

Front Oncol. 2019 Oct 17;9:1060. doi: 10.3389/fonc.2019.01060. eCollection 2019.

Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients.当肿瘤学数据库中没有治疗时间数据时，改良地标法的比较性能：对接受手术的胰腺癌患者的队列研究示例

Clin Epidemiol. 2018 Aug 30;10:1109-1125. doi: 10.2147/CLEP.S160973. eCollection 2018.

Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases.思考时间：选择可能从原发性胰腺癌和肝转移同步切除中获益的患者。

World J Gastroenterol. 2018 Sep 7;24(33):3677-3680. doi: 10.3748/wjg.v24.i33.3677.

Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.药物流行病学研究中癌症患者生存的不朽时间偏倚：不同预后的四种癌症中β受体阻滞剂使用的实证说明。

Eur J Epidemiol. 2017 Nov;32(11):1019-1031. doi: 10.1007/s10654-017-0304-5. Epub 2017 Sep 1.

Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies.新辅助治疗胰腺癌：前瞻性研究的系统评价和荟萃分析。

Cancer Med. 2017 Jun;6(6):1201-1219. doi: 10.1002/cam4.1071. Epub 2017 May 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Neoadjuvant Therapy in Resectable Pancreatic Cancer: Immortal Time Bias and Its Correction.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献